These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 15951629)
1. Prostate cancer cell survival pathways activated by bone metastasis microenvironment. Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629 [TBL] [Abstract][Full Text] [Related]
2. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. Chung LW; Baseman A; Assikis V; Zhau HE J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017 [TBL] [Abstract][Full Text] [Related]
3. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. Loberg RD; Logothetis CJ; Keller ET; Pienta KJ J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478 [TBL] [Abstract][Full Text] [Related]
4. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of bone metastasis in prostate cancer: clinical implications. Msaouel P; Pissimissis N; Halapas A; Koutsilieris M Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):341-55. PubMed ID: 18471791 [TBL] [Abstract][Full Text] [Related]
6. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. Loberg RD; Gayed BA; Olson KB; Pienta KJ J Cell Biochem; 2005 Oct; 96(3):439-46. PubMed ID: 15988761 [TBL] [Abstract][Full Text] [Related]
7. Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy. Lee EC; Tenniswood MP J Cell Biochem; 2004 Mar; 91(4):662-70. PubMed ID: 14991758 [TBL] [Abstract][Full Text] [Related]
8. Current trials using bone-targeting agents in prostate cancer. Tu SM; Lin SH Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481 [TBL] [Abstract][Full Text] [Related]
9. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652 [TBL] [Abstract][Full Text] [Related]
10. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Carducci MA; Jimeno A Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717 [TBL] [Abstract][Full Text] [Related]
15. Role of targeted therapy in the treatment of advanced prostate cancer. Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536 [TBL] [Abstract][Full Text] [Related]
16. A novel model of bone-metastatic prostate cancer in immunocompetent mice. Power CA; Pwint H; Chan J; Cho J; Yu Y; Walsh W; Russell PJ Prostate; 2009 Nov; 69(15):1613-23. PubMed ID: 19585491 [TBL] [Abstract][Full Text] [Related]
17. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Hall CL; Dai J; van Golen KL; Keller ET; Long MW Cancer Res; 2006 Sep; 66(17):8648-54. PubMed ID: 16951179 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of prostate cancer progression to androgen independence. McPhaul MJ Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793 [TBL] [Abstract][Full Text] [Related]
19. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression. Knudsen BS; Miranti CK J Cell Biochem; 2006 Oct; 99(2):345-61. PubMed ID: 16676354 [TBL] [Abstract][Full Text] [Related]
20. New drugs in prostate cancer. Armstrong AJ; Carducci MA Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]